Nabiximols: A new prescription cannabinoid on the horizon

Nabiximols (Sativex) is not FDA-approved for any indication in the US. It’s an oral spray approved in roughly 25-30 countries (UK, Canada, most of Europe) for MS spasticity, but the US market has been the holdout since GW Pharmaceuticals first developed it. Jazz Pharmaceuticals, which now owns the drug, has been running a US-based Phase 3 program to try to change that.